These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34847263)

  • 41. External validation of European Organization for Research and Treatment of Cancer and Spanish Urological Club for Oncological Treatment scoring models to predict recurrence and progression in Japanese patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin.
    Kohjimoto Y; Kusumoto H; Nishizawa S; Kikkawa K; Kodama Y; Ko M; Matsumura N; Hara I
    Int J Urol; 2014 Dec; 21(12):1201-7. PubMed ID: 25074295
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of sarcopenia in patients receiving intravesical Bacillus Calmette-Guérin for non-muscle invasive bladder cancer.
    Alam SM; Larson M; Srinivasan P; Genz N; Fleer R; Sardiu M; Thompson J; Lee E; Hamilton-Reeves J; Wulff-Burchfield E
    Urol Oncol; 2023 Oct; 41(10):431.e15-431.e20. PubMed ID: 37487846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Moreau Strain of Bacillus Calmette-Guerin (BCG) for High-Risk Non-Muscle Invasive Bladder Cancer: An Alternative during Worldwide BCG Shortage?
    Hofbauer SL; Shariat SF; Chade DC; Sarkis AS; Ribeiro-Filho LA; Nahas WC; Klatte T
    Urol Int; 2016; 96(1):46-50. PubMed ID: 26555711
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncologic outcomes of Bacillus Calmette-Guérin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis.
    Aghamir SMK; Khatami F; Farrokhpour H; Oliveira Reis L; Ahmadi Pishkuhi M; Mohammadi A
    PLoS One; 2022; 17(5):e0267934. PubMed ID: 35587916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Murakami Y; Matsumoto K; Miyake M; Amano N; Shimura S; Nishimura N; Iida K; Matsushita Y; Abe T; Yamada T; Uemura M; Matsui Y; Taoka R; Kojima T; Kobayashi T; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K; Iwamura M
    Int J Urol; 2022 Oct; 29(10):1195-1203. PubMed ID: 35858755
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the Bacillus Calmette-Guerin Drug Shortage.
    Chun B; He M; Jones C; Vasan R; Gabriel N; Jacobs BL; Hernandez I; Davies BJ
    Urology; 2023 Jul; 177():74-80. PubMed ID: 36972766
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancer.
    Fadel J; Simonyan D; Fradet V; Lodde M; Lacombe L; Fradet Y; Toren P
    Urol Oncol; 2022 Dec; 40(12):539.e1-539.e8. PubMed ID: 36272848
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
    Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
    World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
    Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
    BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
    Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
    Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
    Sfakianos JP; Kim PH; Hakimi AA; Herr HW
    J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy.
    Nishimura N; Miyake M; Iida K; Miyamoto T; Tomida R; Numakura K; Inokuchi J; Yoneyama T; Matsumura Y; Yajima S; Masuda H; Terada N; Taoka R; Kobayashi T; Kojima T; Matsui Y; Nishiyama N; Kitamura H; Nishiyama H; Fujimoto K
    Int J Urol; 2022 Mar; 29(3):242-249. PubMed ID: 34902876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of the social construct of race on outcomes among bacille Calmette-Guérin-treated patients with high-risk non-muscle-invasive bladder cancer in an equal-access setting.
    Lawler C; Gu L; Howard LE; Branche B; Wiggins E; Srinivasan A; Foster ML; Klaassen Z; De Hoedt AM; Gingrich JR; Theodorescu D; Freedland SJ; Williams SB
    Cancer; 2021 Nov; 127(21):3998-4005. PubMed ID: 34237155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y; Anai S; Tanaka N; Chihara Y; Haramoto M; Otani T; Nakagawa Y; Hirao Y; Konishi N; Fujimoto K
    Int J Urol; 2016 Oct; 23(10):854-860. PubMed ID: 27416975
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of RPL9 predicts the recurrence of non-muscle invasive bladder cancer with BCG therapy.
    Piao XM; Kim YU; Byun YJ; Zheng CM; Moon SM; Kim K; Lee HY; Jeong P; Kang HW; Kim WT; Lee SC; Kim WJ; Yun SJ
    Urol Oncol; 2022 May; 40(5):197.e1-197.e9. PubMed ID: 35382986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.